Dec 15, 2021
Immutep Advances IMP761 Manufacturing
Dec 01, 2021
Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003
Nov 19, 2021
Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha
Nov 14, 2021
Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha
Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway Inhibitor
